Aptinyx Inc (NASDAQ:APTX) had its Outperform rating reiterated by BMO Capital Markets

Analyst Ratings For Aptinyx Inc (NASDAQ:APTX)

Story continues below

Today, BMO Capital Markets reiterated its Outperform rating on Aptinyx Inc (NASDAQ:APTX).

There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Aptinyx Inc (NASDAQ:APTX) is Buy with a consensus target price of $15.00 per share, a potential 271.29% upside.

Some recent analyst ratings include

  • 3/22/2019-Aptinyx Inc (NASDAQ:APTX) had its Outperform rating reiterated by BMO Capital Markets
  • 3/22/2019-Aptinyx Inc (NASDAQ:APTX) had its Overweight rating reiterated by Cantor Fitzgerald with a $12.00 price target
  • 1/17/2019-Aptinyx Inc (NASDAQ:APTX) gets downgraded to Neutral by JPMorgan Chase & Co. with a price target of $8.00
  • 7/16/2018-Aptinyx Inc (NASDAQ:APTX) has coverage initiated with a Outperform rating

    About Aptinyx Inc (NASDAQ:APTX)
    Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

    Recent Trading Activity for Aptinyx Inc (NASDAQ:APTX)
    Shares of Aptinyx Inc closed the previous trading session at 4,04 +0,030 0,75 % with 3.7 shares trading hands.

    An ad to help with our costs